EVOTF News and Press, Evotec SE

2026-01-08 02:01:26 ET More on Evotec SE Evotec: How Low A Company May Go While Still Being Attractive Evotec SE 2025 Q3 - Results - Earnings Call Presentation Evotec SE (EVO) Q3 2025 Earnings Call Transcript Evotec gets $5M milestone payment from Bristol Mye...

Just - Evotec Biologics will optimize monoclonal antibodies ("mAbs") and other biologic modalities Investment enables ten new J.MD ™ projects encompassing molecular optimization including, but not limited to: improved titer, pharmacokinetics, immunogenicity, and stability, over the...

Creation of new Executive Vice President role integrating Global Communications and Investor Relations to strengthen strategic messaging and stakeholder alignment HAMBURG, DE / ACCESS Newswire / January 2, 2026 / Evotec SE (NASDAQ:EVO; Frankfurt Prime Standard:EVT) today announced the app...

2025-12-08 04:10:22 ET There comes a time in an investment where you need to ask yourself whether you are looking at a potential capital loss. For Evotec ( EVO ), I believe that possibility is at least worth asking at this point. Because the company is speculative, I don't hold a bi...

All closing requirements satisfied following announcement of a non-binding term-sheet agreement in July and signing of contract in November Agreement includes approximately US$ 350 m in cash for Just - Evotec Biologics manufacturing site in Toulouse and upfront technology license fees to E...

Phase 2 clinical trial initiated to evaluate SEMA3A mAb as potential treatment for Alport syndrome Milestone payment to Evotec expected upon first dosing of first study participant in early 2026 HAMBURG, DE / ACCESS Newswire / December 4, 2025 / Evotec SE (Frankfurt Stock Exchang...

Milestone payment reflects continued progress under strategic research collaboration addressing high-need patient populations FDA clearance of IND application triggered a US$ 5 m milestone payment to Evotec HAMBURG, DE / ACCESS Newswire / November 12, 2025 / Evotec SE (Frankfurt ...

2025-11-05 12:41:18 ET Evotec SE (EVO) Q3 2025 Earnings Call November 5, 2025 8:00 AM EST Company Participants Volker Braun - Executive VP and Head of Global Investor Relations & ESG Christian Wojczewski - CEO & Management Board Member Paul Hitchin - CFO &a...

Group revenues of € 535.1 m ((7.1)%); Discovery & Preclinical Development segment ("D&PD", (12.3)%) still sees soft demand;Just - Evotec Biologics ("JEB"; +11.3%) above-expectation; further accelerating growth on non-Sandoz / non-DOD business Strong scientific advancements o...

2025-11-04 17:02:40 ET More on Evotec SE, Sandoz Group AG Sandoz Group AG (SDZNY) Q3 2025 Sales Call Transcript Sandoz Group AG (SDZNY) Q3 2025 Sales/ Trading Statement Call - Slideshow Evotec SE (EVO) Q2 2025 Earnings Call Transcript Regeneron settles patent...